Functional training for persons with multiple sclerosis

Phase 3

• Conditions: G35; Multiple sclerosis

• Registration Number: DRKS00017091
• Lead Sponsor: Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-04-05
• Study Completion: 2023-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Relapsing remitting multiple sclerosis; EDSS-Scale (Expanded Disability Status Scale): 0-4

Exclusion Criteria

Acute episode or exacerbation of multiple sclerosis symptoms during intervention,
cardiac preload,
concomitant disease state (internistic or neurological) affecting study end points (e.g. tumor diseases),
orthopaedic diseases excluding from the exercise program,
pregnancy or breast feeding

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
matrix-metalloproteinases in the Serum (t0, t1, t2)

Secondary Outcome Measures

Name	Time	Method
umber and proportions of further circulating immune markers associated with MS and exercise (t0, t1, t2): <br>metabolites of the Tryptophan-Kynurenine pathway and enzymes, cytokines, lipid markers and T-cells <br><br>Strength (t0, t2): <br>Hypothetical One Repetition Maximum strength in relevant muscle groups <br><br>Endurance capacity (t0, t2): <br>Peak oxygen uptake (VO2peak) reflecting their cardiorespiratory fitness measured during a maximal incremental exercise test on a cycle ergometer.<br><br>Further secondary outcomes: actigraphic data (t0, t1, t2); body composition (BIA) (t0, t2)<br>cognitive Performance (t0, t2), i.e. information processing speed, verbal memory and visual memory; questionnaires to measure fatigue (t0, t2), depression (t0, t2), sleeping quality (t0, t2) and quality of life (t0, t2)